Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8399445 | CUMBERLAND PHARMS | Acetylcysteine composition and uses thereof |
Aug, 2025
(2 years from now) | |
US8653061 | CUMBERLAND PHARMS | Acetylcysteine composition and uses thereof |
Aug, 2025
(2 years from now) | |
US8148356 | CUMBERLAND PHARMS | Acetylcysteine composition and uses therefor |
May, 2026
(3 years from now) | |
US9327028 | CUMBERLAND PHARMS | Acetylcysteine compositions and methods of use thereof |
Jul, 2031
(8 years from now) | |
US8722738 | CUMBERLAND PHARMS | Acetycysteine compositions and methods of use thereof |
Apr, 2032
(9 years from now) |
Drugs and Companies using ACETYLCYSTEINE ingredient
Market Authorisation Date: 23 January, 2004
Treatment: Method of treating acetaminophen overdose with acetylcysteine solutions; Composition and method for providing a reduction in side effects for human patients in need of acetylcysteine therapy
Dosage: INJECTABLE;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9138404 | CUMBERLAND PHARMS | Treating critically ill patients with intravenous ibuprofen |
Sep, 2029
(6 years from now) | |
US9114068 | CUMBERLAND PHARMS | Treating patients with intravenous ibuprofen |
Sep, 2029
(6 years from now) | |
US8735452 | CUMBERLAND PHARMS | Treating patients with intravenous ibuprofen |
Sep, 2029
(6 years from now) | |
US9649284 | CUMBERLAND PHARMS | Treating critically ill patients with intravenous ibuprofen |
Sep, 2029
(6 years from now) | |
US8871810 | CUMBERLAND PHARMS | Treating critically ill patients with intravenous ibuprofen |
Sep, 2029
(6 years from now) | |
US9295639 | CUMBERLAND PHARMS | Treating critically ill patients with intravenous ibuprofen |
Sep, 2029
(6 years from now) | |
US9012508 | CUMBERLAND PHARMS | Administration of intravenous ibuprofen |
Sep, 2030
(7 years from now) | |
US9072661 | CUMBERLAND PHARMS | Injectable ibuprofen formulation |
Mar, 2032
(9 years from now) | |
US9072710 | CUMBERLAND PHARMS | Injectable ibuprofen formulation |
Mar, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M | Nov 19, 2024 |
Drugs and Companies using IBUPROFEN ingredient
Market Authorisation Date: 11 June, 2009
Treatment: Methods of treating pain, inflammation and/or fever in a critically ill patient with intravenous ibuprofen in need thereof; Methods of treating pain, inflammation and/or fever with intravenous ibuprofen such that mean arterial blood pressure does not increase the dosage interval; Management of mild to moderate pain, management of moderate to severe pain as an adjunct to opioid analgesics, reduction in fever through anti-inflammatory, analgesic, and antipyretic activity; Management of mild to moderate pain, management of moderate to severe pain as an adjunct to opioid analgesics in a critically ill patient with intravenous ibuprofen in need thereof; Methods of treating pain, inflammation, fever, patent ductus arteriosis with aqueous composition; Methods of making aqueous composition and treating pain, inflammation, fever, patent ductus arteriosis with aqueous composition
Dosage: SOLUTION;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6635618 | CUMBERLAND PHARMS | Glycopeptide phosphonate derivatives |
Sep, 2023
(7 months from now) | |
US7531623 | CUMBERLAND PHARMS | Hydrochloride salts of a glycopeptide phosphonate derivative |
Jan, 2027
(3 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6858584 | CUMBERLAND PHARMS | Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin |
Aug, 2022
(5 months ago) |
Drugs and Companies using TELAVANCIN HYDROCHLORIDE ingredient
Market Authorisation Date: 11 September, 2009
Treatment: Method for treating bacterial infection
Dosage: POWDER;INTRAVENOUS
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic